Targeting non-coding RNAs to overcome cancer therapy resistance
BQ Chen, MP Dragomir, C Yang, Q Li, D Horst… - Signal transduction and …, 2022 - nature.com
It is now well known that non-coding RNAs (ncRNAs), rather than protein-coding transcripts,
are the preponderant RNA transcripts. NcRNAs, particularly microRNAs (miRNAs), long non …
are the preponderant RNA transcripts. NcRNAs, particularly microRNAs (miRNAs), long non …
New advances in the diagnosis and management of hepatocellular carcinoma
JD Yang, JK Heimbach - Bmj, 2020 - bmj.com
Hepatocellular carcinoma is one of the leading causes of cancer related death in the world.
Biannual surveillance for the disease in patients with cirrhosis and in high risk carriers of …
Biannual surveillance for the disease in patients with cirrhosis and in high risk carriers of …
CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1
Sorafenib is the first-line chemotherapeutic therapy for advanced hepatocellular carcinoma
(HCC). However, sorafenib resistance significantly limits its therapeutic efficacy, and the …
(HCC). However, sorafenib resistance significantly limits its therapeutic efficacy, and the …
Recent advances in systemic therapy for hepatocellular carcinoma
H Zhang, W Zhang, L Jiang, Y Chen - Biomarker Research, 2022 - Springer
Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in
the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially …
the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially …
N6-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling
J Xu, Z Wan, M Tang, Z Lin, S Jiang, L Ji, K Gorshkov… - Molecular cancer, 2020 - Springer
Background and aims Accumulating evidence suggests that the primary and acquired
resistance of hepatocellular carcinoma (HCC) to sorafenib is mediated by multiple …
resistance of hepatocellular carcinoma (HCC) to sorafenib is mediated by multiple …
Molecular therapies for HCC: Looking outside the box
S Faivre, L Rimassa, RS Finn - Journal of hepatology, 2020 - Elsevier
Over the past decade, sorafenib has been the only systemic agent with proven clinical
efficacy for patients with unresectable hepatocellular carcinoma (HCC). Recently, lenvatinib …
efficacy for patients with unresectable hepatocellular carcinoma (HCC). Recently, lenvatinib …
Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer
H Shen, B Liu, J Xu, B Zhang, Y Wang, L Shi… - Journal of Hematology & …, 2021 - Springer
Background Hepatocellular carcinoma (HCC) is one of the most common malignancies
globally. Despite aggressive and multimodal treatment regimens, the overall survival of HCC …
globally. Despite aggressive and multimodal treatment regimens, the overall survival of HCC …
Targeted therapy for hepatocellular carcinoma: Challenges and opportunities
S Chen, Q Cao, W Wen, H Wang - Cancer letters, 2019 - Elsevier
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, which
ranks as the sixth of cancer-related death. Despite the emergence of targeted therapy …
ranks as the sixth of cancer-related death. Despite the emergence of targeted therapy …
Sorafenib: a review in hepatocellular carcinoma
GM Keating - Targeted oncology, 2017 - Springer
Sorafenib (Nexavar®) is currently the only systemic agent approved for use in hepatocellular
carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib …
carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib …
Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis
J Feng, W Dai, Y Mao, L Wu, J Li, K Chen, Q Yu… - Journal of Experimental …, 2020 - Springer
Background Hepatocellular carcinoma (HCC) is a common primary malignant tumor which
usually progresses to an advanced stage because of late diagnosis. Sorafenib (Sora) is a …
usually progresses to an advanced stage because of late diagnosis. Sorafenib (Sora) is a …